Literature DB >> 12819072

Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.

Christian Theilacker1, Fadie T Coleman, Simone Mueschenborn, Nicolas Llosa, Martha Grout, Gerald B Pier.   

Abstract

Deterioration of lung function in patients with cystic fibrosis (CF) is closely associated with chronic pulmonary infection with mucoid Pseudomonas aeruginosa. The mucoid exopolysaccharide (MEP) from P. aeruginosa has been shown to induce opsonic antibodies in mice that are protective against this chronic infection. MEP-specific opsonic antibodies are also commonly found in the sera of older CF patients lacking detectable P. aeruginosa infection. When used in a human vaccine trial, however, MEP only minimally induced opsonic antibodies. To evaluate whether conjugation of MEP to a carrier protein could improve its immunogenicity, we bound thiolated MEP to keyhole limpet hemocyanin (KLH) by using succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) as a linker. In contrast to the native MEP polymer, the MEP-KLH conjugate vaccine induced high titers of MEP-specific immunoglobulin G (IgG) in C3H-HeN mice and in a rabbit. Sera from mice immunized with MEP-KLH conjugate, but not from animals immunized with comparable doses of native MEP, demonstrated opsonic killing activity. Vaccination with MEP-KLH conjugate induced opsonic antibodies broadly cross-reactive to heterologous mucoid strains of P. aeruginosa. Preexisting nonopsonic antibodies to MEP are found in normal human sera, including young CF patients, and their presence impedes the induction of opsonic antibodies. Induction of nonopsonic antibodies by either intraperitoneal injection of MEP or injection or feeding of the cross-reactive antigen, seaweed alginate, reduced the level of overall IgG elicited by follow-up immunization with the MEP-KLH conjugate. However, the opsonic activity was lower only in the sera of MEP-KLH conjugate-immunized mice with preexisting antibodies induced by MEP but not with antibodies induced by seaweed alginate. Immunization with MEP-KLH elicited a significant proportion of antibodies specific to epitopes involving O-acetate residues, and this subpopulation of antibodies mediated opsonic killing of mucoid P. aeruginosa in vitro. These results indicate that conjugation of MEP to KLH significantly enhances its immunogenicity and the elicitation of opsonic antibodies in mice and rabbits, that the conjugate induces opsonic antibodies in the presence of preexisting nonopsonic antibodies, and that opsonic antibodies to MEP are directed at epitopes that include acetate residues on the uronic acid polymer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819072      PMCID: PMC162014          DOI: 10.1128/IAI.71.7.3875-3884.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Monomer sequence and acetylation pattern in some bacterial alginates.

Authors:  G Skjåk-Braek; H Grasdalen; B Larsen
Journal:  Carbohydr Res       Date:  1986-10-15       Impact factor: 2.104

2.  Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope.

Authors:  F Michon; C H Huang; E K Farley; L Hronowski; J Di; P C Fusco
Journal:  Dev Biol (Basel)       Date:  2000

3.  Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide.

Authors:  C V Garner; D DesJardins; G B Pier
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

4.  Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.

Authors:  S C Szu; A L Stone; J D Robbins; R Schneerson; J B Robbins
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

5.  Genetic mapping of chromosomal determinants for the production of the exopolysaccharide alginate in a Pseudomonas aeruginosa cystic fibrosis isolate.

Authors:  D E Ohman; A M Chakrabarty
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

6.  The purification and chemical characterisation of the alginate present in extracellular material produced by mucoid strains of Pseudomonas aeruginosa.

Authors:  V Sherbrock-Cox; N J Russell; P Gacesa
Journal:  Carbohydr Res       Date:  1984-12-15       Impact factor: 2.104

7.  Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis.

Authors:  G B Pier; J M Saunders; P Ames; M S Edwards; H Auerbach; J Goldfarb; D P Speert; S Hurwitch
Journal:  N Engl J Med       Date:  1987-09-24       Impact factor: 91.245

8.  O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.

Authors:  P A van de Wiel; M H Witvliet; D Evenberg; H J Derks; E C Beuvery
Journal:  Vaccine       Date:  1987-03       Impact factor: 3.641

9.  Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients.

Authors:  G B Pier; D Desjardins; T Aguilar; M Barnard; D P Speert
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

10.  Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Authors:  Z Kossaczka; F Y Lin; V A Ho; N T Thuy; P Van Bay; T C Thanh; H B Khiem; D D Trach; A Karpas; S Hunt; D A Bryla; R Schneerson; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.609

View more
  28 in total

1.  Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa.

Authors:  Clement Mugabe; Majed Halwani; Ali O Azghani; Robert M Lafrenie; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Streptococcus pneumoniae serotype 9A isolates contain diverse mutations to wcjE that result in variable expression of serotype 9V-specific epitope.

Authors:  Juan J Calix; Melissa B Oliver; Logan K Sherwood; Bernard W Beall; Susan K Hollingshead; Moon H Nahm
Journal:  J Infect Dis       Date:  2011-09-09       Impact factor: 5.226

3.  Structural characterization of Streptococcus pneumoniae serotype 9A capsule polysaccharide reveals role of glycosyl 6-O-acetyltransferase wcjE in serotype 9V capsule biosynthesis and immunogenicity.

Authors:  Juan J Calix; Jamil S Saad; Allison M Brady; Moon H Nahm
Journal:  J Biol Chem       Date:  2012-02-24       Impact factor: 5.157

4.  Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model.

Authors:  Alessandra Bragonzi; Dieter Worlitzsch; Gerald B Pier; Petra Timpert; Martina Ulrich; Morten Hentzer; Jens Bo Andersen; Michael Givskov; Massimo Conese; Gerd Doring
Journal:  J Infect Dis       Date:  2005-06-24       Impact factor: 5.226

Review 5.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

6.  Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia.

Authors:  Paola Marcato; Thomas P Griener; George L Mulvey; Glen D Armstrong
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during Polymicrobial Airway Infections.

Authors:  Melissa S McDaniel; Trenton Schoeb; W Edward Swords
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

8.  Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines.

Authors:  Victoria L Campodónico; Nicolás J Llosa; Martha Grout; Gerd Döring; Tomás Maira-Litrán; Gerald B Pier
Journal:  Infect Immun       Date:  2009-12-07       Impact factor: 3.441

9.  Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice.

Authors:  David Skurnik; Massimo Merighi; Martha Grout; Mihaela Gadjeva; Tomas Maira-Litran; Maria Ericsson; Donald A Goldmann; Susan S Huang; Rupak Datta; Jean C Lee; Gerald B Pier
Journal:  J Clin Invest       Date:  2010-08-25       Impact factor: 14.808

10.  Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens.

Authors:  Marina L Gening; Tomás Maira-Litrán; Andrea Kropec; David Skurnik; Martha Grout; Yury E Tsvetkov; Nikolay E Nifantiev; Gerald B Pier
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.